DK0697859T3 - Stabile, orale og absorberbare terapeutiske præparater af NADP og NADPH - Google Patents

Stabile, orale og absorberbare terapeutiske præparater af NADP og NADPH

Info

Publication number
DK0697859T3
DK0697859T3 DK94914734.2T DK94914734T DK0697859T3 DK 0697859 T3 DK0697859 T3 DK 0697859T3 DK 94914734 T DK94914734 T DK 94914734T DK 0697859 T3 DK0697859 T3 DK 0697859T3
Authority
DK
Denmark
Prior art keywords
nadph
stable
oral
nadp
therapeutic preparations
Prior art date
Application number
DK94914734.2T
Other languages
Danish (da)
English (en)
Inventor
Joerg G D Birkmayer
Original Assignee
Birkmayer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21995236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0697859(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Birkmayer Pharmaceuticals Inc filed Critical Birkmayer Pharmaceuticals Inc
Application granted granted Critical
Publication of DK0697859T3 publication Critical patent/DK0697859T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK94914734.2T 1993-04-29 1994-03-25 Stabile, orale og absorberbare terapeutiske præparater af NADP og NADPH DK0697859T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/055,049 US5332727A (en) 1993-04-29 1993-04-29 Stable, ingestable and absorbable NADH and NADPH therapeutic compositions

Publications (1)

Publication Number Publication Date
DK0697859T3 true DK0697859T3 (da) 1997-12-29

Family

ID=21995236

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94914734.2T DK0697859T3 (da) 1993-04-29 1994-03-25 Stabile, orale og absorberbare terapeutiske præparater af NADP og NADPH

Country Status (16)

Country Link
US (1) US5332727A (zh)
EP (1) EP0697859B1 (zh)
JP (1) JP3683582B2 (zh)
CN (1) CN1072483C (zh)
AT (1) ATE153853T1 (zh)
AU (1) AU674583B2 (zh)
BR (1) BR9406514A (zh)
CA (1) CA2161641C (zh)
DE (1) DE69403656T2 (zh)
DK (1) DK0697859T3 (zh)
ES (1) ES2103587T3 (zh)
GR (1) GR3024561T3 (zh)
IL (1) IL109186A (zh)
MX (1) MX9402938A (zh)
TW (1) TW336895B (zh)
WO (1) WO1994025007A1 (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735293A1 (en) * 1995-01-17 1996-07-18 Menuco Corp. Nadh and nadph therapeutic agents for dermal administration
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
US6340474B1 (en) 1999-08-03 2002-01-22 Charles A. Mesko Composition for potentiating a growth hormone and a method for preparation of said composition
IT1318565B1 (it) * 2000-06-09 2003-08-27 World Pharma Tech Ltd Integratore alimentare proenergetico a base di nadh octocosanolo evitamina e.
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
AR034813A1 (es) * 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
ITBO20020140A1 (it) * 2002-03-21 2003-09-22 Valpharma Sa Formulazioni a base di nadh in forma di multiparticolato con rivestimento gastroresistente o a rilascio modificato
AT502435B1 (de) * 2002-11-19 2008-01-15 Oekopharm Forschungs Und Entwi Pharmazeutische zusammensetzung umfassend ein wasserstoffübertragendes coenzym und chlorophyll
AU2003289288A1 (en) * 2002-12-03 2004-06-23 Kyowa Hakko Kogyo Co., Ltd. Method of stabilizing reduced nicotinamide adenine dinucleotide or reduced nicotinamide adenine dinucleotide phosphate
US20040126751A1 (en) * 2002-12-27 2004-07-01 Birkmayer Jorg G.D. Method of prolonging the life-span of living cells using NADH, NADPH and ADP-ribose
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
PE20060167A1 (es) * 2004-04-08 2006-04-20 Wyeth Corp Formulaciones de dispersion solida que comprende acetato de bazedoxifeno
AU2005233128A1 (en) * 2004-04-08 2005-10-27 Wyeth Bazedoxifene ascorbate as selective estrogen receptor modulator
WO2006073162A1 (ja) * 2005-01-07 2006-07-13 Kyowa Hakko Kogyo Co., Ltd. Nadhもしくはnadphまたはその塩の保存安定性向上方法
WO2006106805A1 (ja) * 2005-03-30 2006-10-12 Kyowa Hakko Kogyo Co., Ltd. 物質の保存安定性向上方法
ITMI20060629A1 (it) * 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
ITMI20071374A1 (it) 2007-07-10 2009-01-11 Gnosis Spa Sali stabili di s-adenosilmetionina e processo per il loro ottenimento.
US20100200237A1 (en) * 2009-02-12 2010-08-12 Colgate Sam O Methods for controlling temperatures in the environments of gas and oil wells
US20100236784A1 (en) * 2009-03-20 2010-09-23 Horton Robert L Miscible stimulation and flooding of petroliferous formations utilizing viscosified oil-based fluids
US20100252259A1 (en) * 2009-04-01 2010-10-07 Horton Robert L Oil-based hydraulic fracturing fluids and breakers and methods of preparation and use
US20100263867A1 (en) * 2009-04-21 2010-10-21 Horton Amy C Utilizing electromagnetic radiation to activate filtercake breakers downhole
DE102012104451A1 (de) * 2012-05-23 2013-11-28 Jürgen Ruhlmann Komposition zur Behandlung einer Störung des circadianen Rhythmus
KR102322197B1 (ko) * 2014-04-08 2021-11-09 뉴트리션 ＆ 바이오사이언시즈 유에스에이 1, 엘엘씨 에스테르화된 셀룰로오스 에테르를 포함하는 분산물
RU2545920C1 (ru) * 2014-04-23 2015-04-10 Аллан Герович Бениашвили Композиция nadh, обладающая антиоксидантными свойствами
EP2944312B1 (de) 2014-05-16 2022-01-26 TP Tumapharma Ltd Kombinationspräparat, umfassend glucosamin und chondroitinsulfat
CN104840479A (zh) * 2015-02-17 2015-08-19 苏州人本药业有限公司 Nadph在制备治疗心脏疾病药物中的应用
CN104758307A (zh) * 2015-03-16 2015-07-08 邦泰生物工程(深圳)有限公司 Nadh和nmn在制备帕金森病药物或保健品的应用
CN109562120B (zh) * 2017-08-11 2021-03-19 邦泰生物工程(深圳)有限公司 一种含有nadh和nadph的组合物及其应用
CN109893510A (zh) * 2019-02-28 2019-06-18 合肥康诺药物开发有限公司 一种辅酶i肠溶片及其制备方法
BR102020013862A2 (pt) * 2020-07-07 2022-01-18 Edson Luiz Peracchi Implante subcutâneo reabsorvível de longa duração com liberação sustentada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da doença de parkinson
DE202022000567U1 (de) 2022-03-06 2022-03-16 Penta Phi Eg Liposomale Formulierung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1930059C3 (de) * 1969-06-13 1975-11-13 Boehringer Mannheim Gmbh Stabilisiertes Nicotinamid-adenindinucleotid oder bzw. und Nicotinamld-adenin-dinucleotidphosphat
GB1359643A (en) * 1970-09-28 1974-07-10 Controlled Medications Controlled release medicament
CA1187388A (en) * 1978-09-20 1985-05-21 American Monitor Corporation Stabilization of working reagent solutions containing nadh, nadph, and/or enzymes, and the use of such stabilized reagents in enzymes or substrate assays
JPS5748908A (en) * 1980-09-08 1982-03-20 Kyorin Pharmaceut Co Ltd Prolonged release type nicomol pharmaceutical
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS59227817A (ja) * 1983-06-07 1984-12-21 Toyo Jozo Co Ltd 持続性経口用ブレデニン製剤
JPS6144811A (ja) * 1984-08-10 1986-03-04 Ss Pharmaceut Co Ltd 徐放性ジクロフエナクナトリウム製剤
CA1336169C (en) * 1988-03-01 1995-07-04 Walther Birkmayer Agent for treatment of parkinson's disease
JPH01308231A (ja) * 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 安定化された医薬組成物および製造法
AT397201B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms

Also Published As

Publication number Publication date
IL109186A0 (en) 1994-06-24
TW336895B (en) 1998-07-21
DE69403656T2 (de) 1997-10-16
DE69403656D1 (de) 1997-07-10
US5332727A (en) 1994-07-26
CA2161641C (en) 1999-06-15
ATE153853T1 (de) 1997-06-15
CA2161641A1 (en) 1994-11-10
EP0697859A1 (en) 1996-02-28
CN1121688A (zh) 1996-05-01
CN1072483C (zh) 2001-10-10
MX9402938A (es) 1995-01-31
JP3683582B2 (ja) 2005-08-17
EP0697859A4 (en) 1996-06-26
EP0697859B1 (en) 1997-06-04
WO1994025007A1 (en) 1994-11-10
IL109186A (en) 2000-01-31
GR3024561T3 (en) 1997-12-31
AU674583B2 (en) 1997-01-02
AU6698094A (en) 1994-11-21
BR9406514A (pt) 1996-01-09
JPH08512021A (ja) 1996-12-17
ES2103587T3 (es) 1997-09-16

Similar Documents

Publication Publication Date Title
DK0697859T3 (da) Stabile, orale og absorberbare terapeutiske præparater af NADP og NADPH
DE69701532D1 (de) Orale zusammensetzung gegen zahnbelag
DK1213015T3 (da) Oralt farmaceutisk præparat med forsinket frigivelse af protonpumpeinhibitorer
EP0828485A4 (en) USE OF THE R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDANE, ITS SALTS AND COMPOSITIONS
DK0841904T3 (da) Orale farmaceutiske præparater med forsinket frigivelse af reversible protonpumpeinhibitorer
EP2261200A3 (en) Modified forms of pharmacacologically active agents and uses therefor
AU7702291A (en) Dietary fiber, its process and physiologically active composition containing the same as an active ingredient
NZ314442A (en) Extended release formulation comprising venlafaxine hydrochloride, film coating composition
IS1812B (is) Meðferðaefnasambönd, lyfjafræðilega hæf sölt og samsetningar sem innihalda efnasamböndin, ásamt notkun þeirra
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
NO954878L (no) Pyrrolderivater
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
IS4553A (is) Lyfjablöndur sem innihalda mónóamín oxídasa B blokkara
AU4830097A (en) Use of an extract of Cimicifuga
MY121864A (en) Condensed thienopyrimidines with phosphodiesterase-v inhibiting action.
AU5686196A (en) Use of an "immunodeficiency-virus suppressing lymphokine (ISL)" to inhibit the replication of viruses, in particular of retroviruses
EP0345248A3 (de) Verwendung des Enzym-Cofaktors NADPH zur Herstellung eines Arzneimittels sowie daraus hergestelltes Arzneimittel und Verfahren zu seiner Herstellung
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
NO922842D0 (no) Benzotiazolderivater, fremgangsmaate for deres fremstilling og deres anvendelse som terapeutika
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
NO993435L (no) Transdermalt acetylsalicylsyre inneholdende terapeutisk system med forsterket resorpsjon
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner
DK1062954T3 (da) Anvendelse af itakonsyre til regulering af det glykotiske stofskifte
NO895049D0 (no) Fremgangsmaate for tilvirkning av polyorganosiloksan og ensammensetning som er utherdbar med straaling.